|1.||Katz, Jonathan L: 4 articles (01/2014 - 06/2003)|
|2.||Newman, Amy Hauck: 4 articles (01/2008 - 09/2002)|
|3.||Kopajtic, Theresa: 2 articles (10/2006 - 06/2003)|
|4.||Cao, Jianjing: 2 articles (10/2006 - 06/2003)|
|5.||Soto, Paul L: 1 article (01/2014)|
|6.||Kuo, Chang-Hung: 1 article (01/2014)|
|7.||Yang, Pinchen: 1 article (01/2014)|
|8.||Wang, Peng-Wei: 1 article (01/2014)|
|9.||Tanda, Gianluigi: 1 article (01/2014)|
|10.||Tsai, Jui-Hsiu: 1 article (01/2014)|
|1.||Cocaine-Related Disorders (Cocaine Addiction)
01/01/2014 - "Atypical dopamine-uptake inhibitors have low abuse potential and may serve as leads for development of cocaine-abuse treatments. "
06/19/2003 - "Both dopamine uptake inhibitors and sigma(1) receptor antagonists have been implicated as potential pharmacotherapeutics for the treatment of cocaine abuse. "
03/11/1999 - "Synthesis and pharmacology of site-specific cocaine abuse treatment agents: 2-(aminomethyl)-3-phenylbicyclo[2.2.2]- and -[2.2.1]alkane dopamine uptake inhibitors."
01/01/2006 - "The discovery and preclinical development of selective dopamine reuptake inhibitors as potential pharmacotherapies for treating cocaine addiction are presented. "
06/01/2006 - "The potential of d-amphetamine as an effective treatment for cocaine abuse and negative clinical results with dopamine uptake inhibitors suggest that differences in shifts in dose-effect curves should be further examined with emerging clinical data as a predictive index of potential treatments for cocaine abuse."
|2.||Parkinson Disease (Parkinson's Disease)
03/01/2005 - "Dopamine uptake inhibitors may provide a means of sustaining endogenous and exogenous striatal dopamine levels in Parkinson's disease, but most are not selective and also inhibit the noradrenaline and 5-hydroxytryptamine (5-HT) transporters. "
03/01/1996 - "Other therapies in the early stages of Parkinson's disease may include neuroprotective agents, dopamine agonists, dopamine reuptake inhibitors, anticholinergics and/or amantadine. "
01/01/2007 - "The symptomatic therapy of motor behaviour in Parkinson's disease, based on l-DOPA, is registering adenosine A(2A) receptor antagonists, monoamine oxidase B inhibitors and ion channel modulators, as well as dopamine uptake inhibitors and glutamate AMPA receptor antagonists. "
|3.||Movement Disorders (Movement Disorder)
01/01/1988 - "Neostriatal dopamine uptake and reversal of age-related movement disorders with dopamine-uptake inhibitors."
12/15/1994 - "Anticholinergics or dopamine-reuptake inhibitors should be considered before clozapine is given to patients with tardive dyskinesia because of clozapine's potential for serious adverse effects. "
|5.||Heroin Dependence (Heroin Abuse)
|2.||Cocaine (Cocaine HCl)
|4.||Cholinergic Antagonists (Anticholinergics)
|7.||Adenosine A2A Receptor (Adenosine A2A Receptors)
|8.||Glutamic Acid (Glutamate)
|10.||Dopamine Agonists (Dopamine Agonist)
|2.||Drug Therapy (Chemotherapy)